April 18, 2025

Mirco Friedrich: Forbes-List “30 Under 30 Europe”

Mirco Friedrich: Forbes-List “30 Under 30 Europe”

Mirco Julian Friedrich from the DKFZ, HI-STEM* and Heidelberg University Hospital (UKHD) was included in the renowned Forbes ‘30 Under 30 Europe’ list in the Science & Healthcare category.

The physician and cancer researcher, who has headed the Haematology and Immune Engineering junior research group since this year, initially developed successful approaches to reactivate the immune system against brain tumours.

With his current research, Friedrich aims to develop innovative strategies to reprogramme the human immune system by integrating synthetic immunology, genome editing and AI-controlled bioengineering. The aim is to prevent cancer, strengthen immune resilience and promote healthy ageing.

With this award, the US business magazine Forbes annually recognises outstanding young personalities under the age of 30 who stand out in their fields through their innovative strength, social relevance and exceptional achievements.


*The Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM) gGmbH was founded in 2008 as a public-private partnership between the DKFZ and the Dietmar Hopp Foundation.

Our latest News

discover more
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates

Ladenburg, Germany, 28 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its wholly-owned subsidiary, Heidelberg Pharma Research GmbH, has signed a new collaboration agreement with its strategic partner Huadong Medicine Co., Ltd., Hangzhou, China. Huadong Medicine is the second-largest shareholder of Heidelberg Pharma […]

Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China

Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China

Ladenburg, Germany, 26 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin (HDP-101), the Company’s novel BCMA-targeting ADC, in combination therapy for the […]

Cells Have an Early-Warning System for Stress in Mitochondria

Cells Have an Early-Warning System for Stress in Mitochondria

Internal protective mechanism responds to the very first signs of mitochondrial dysfunction Mitochondria – the powerhouses of the cell – have their own monitoring system that detects oxidative stress at a very early stage. It activates protective mechanisms even before the damage caused by this stress can spread to the rest of the cell. This […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp